# UC Irvine UC Irvine Previously Published Works

# Title

ASSOCIATION OF ERYTHROPOESIS STIMULATING AGENT INDEX (ESAI) HYPORESPONSIVENESS WITH MORTALITY IN NON-DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS AND EFFECT MODIFICATION BY PLATELET

#### Permalink

https://escholarship.org/uc/item/6f6725dv

## Journal

AMERICAN JOURNAL OF KIDNEY DISEASES, 59(4)

## ISSN

0272-6386

# **Authors**

Kaur, Suchet Lu, Jun L Kalantar-Zadeh, Kamyar <u>et al.</u>

Publication Date 2012

## **Copyright Information**

This work is made available under the terms of a Creative Commons Attribution License, available at <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>

Peer reviewed

# A46

Am J Kidney Dis. 2012;59(4):A1-A92

# 126

#### ASSOCIATION OF ERYTHROPOESIS STIMULATING AGENT INDEX (ESAI) HYPORESPONSIVENESS WITH MORTALITY IN NON-DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS AND EFFECT MODIFICATION BY PLATELET

<u>Suchet Kaur</u>, Carilion Clinic, Roanoke, Virginia; Jun L Lu, Salem Research Institute, Salem, Virginia; Kamyar Kalantar-Zadeh, Harbor-UCLA, Torrance, California; Csaba P Kovesdy, Salem VA Medical Center, Salem, Virginia.

ESA therapy targeting higher hemoglobin may be harmful due to offtarget effects of higher ESA doses, like inducing thrombocytosis.

We examined the association between ESAi (the ratio of weekly ESA dose and blood hemoglobin) and all-cause mortality in 1,232 males with CKD stage 1-5 of which 585 patients died (mortality rate, 95%CI: 117/1000 patient-years (108-127)) over a median follow-up 3.6 years. Associations of time-varying ESAi with pre-dialysis mortality overall and in subgroups with different platelet counts were examined in Cox models with adjustment for demographics, comorbidities and labs. Nonlinear associations were explored by using cubic splines.

A one log-unit higher ESAi was associated with a mortality hazard ratio (95%CI) of 1.95 (1.25-3.02), p=0.003). Compared to patients on no ESA, in those with ESAi >1200 the adjusted HR of mortality (95% CI) in patients with platelet counts of <130, 130-320 and >320 was 2.3 (0.9-6.0), 1.2 (0.5-2.5) and 3.1 (0.6-15.4).

Increasing ESAi is associated with higher mortality in patients with moderate and advanced NDD-CKD. This could be mediated by changes in platelet counts

